Metagenomi Therapeutics
48 hedge funds and large institutions have $8.65M invested in Metagenomi Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.84% less ownership
Funds ownership: 18.02% → 17.18% (-0.84%)
14% less funds holding
Funds holding: 56 → 48 (-8)
21% less capital invested
Capital invested by funds: $11M → $8.65M (-$2.31M)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$594K |
| 2 |
Renaissance Technologies
New York
|
+$248K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$130K |
| 4 |
Two Sigma Investments
New York
|
+$86K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$439K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$250K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$105K |
| 4 |
Millennium Management
New York
|
-$101K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$80.2K |
MGX Hedge Fund Activity: Q1 2026 in Review
48 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2026, worth a combined $8.65M — down 21% from $11M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MGX and 5 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $594K. The largest seller was Jane Street, cutting an estimated $439K.
- 48 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2026, down from 56 in Q4 2025.
- Funds reported $8.65M of Metagenomi Therapeutics stock for Q1 2026, down 21% quarter-over-quarter.
- 5 funds opened new Metagenomi Therapeutics positions in Q1 2026 and 12 closed out, a net change of -7 holders.
- The largest Metagenomi Therapeutics buyer in Q1 2026 was Jacobs Levy Equity Management, an estimated $594K added.
- The largest Metagenomi Therapeutics seller in Q1 2026 was Jane Street, an estimated $439K sold.
Based on aggregated 13F filings for Q1 2026.